Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants between the ages of 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities).~* Body mass index (BMI) between 18-27 kilograms per meter squared (kg/m\^2), inclusive.~* Total body weight \>65 kilograms (kg) (143 pounds \[lb\]) for men and \>46 kg (101 lb) for women.~* Decision making capacity and willingness to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including adequate venous access.~* Vital signs (blood pressure \[BP\], pulse rate, body temperature) within normal range or, if out of range, assessed by the Principal Investigator as not clinically significant.~* Fasting blood glucose level \<100 milligrams per deciliter (mg/dL) at screening.~* A negative serum pregnancy test (if female of childbearing potential).~* Female participants of childbearing potential must agree to practice effective birth control or abstinence currently and agree to continue to do so for the duration of their time on study.~* Signed, written institutional review board (IRB)-approved informed consent.~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, oncologic, or neurologic (to include history of seizures) disease; hypoglycemic episodes; intercurrent illness (such as influenza); or allergic disease (including severe drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Clinical significance to be determined by the Principal Investigator.~* As judged by the investigator, clinically significant findings in routine laboratory data. (Anemia with hematocrit less than 33% at screening is specifically exclusionary.)~* Known history of diabetes mellitus (type 1 or type 2) or gestational diabetes.~* Known allergy to hyaluronidase or any other ingredient in the study drug.~* Positive human immunodeficiency virus (HIV) 1, hepatitis B, or hepatitis C antibody test.~* History or evidence of alcohol or drug abuse.~* History or evidence of use of any tobacco- or nicotine-containing product within 6 months prior to screening and a screening qualitative urine nicotine test.~* Use of drugs that may interfere with the interpretation of study results or are known to cause clinically relevant interference with insulin action or glucose utilization.~* Blood donation or high volume phlebotomy, for example, \>100 milliliters (mL), within 56 days before dosing.~* Participation in a study of any investigational drug or device 30 days before enrollment in this study.~* The participant is unfit for the study in the opinion of the investigator.~* Women who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Lispro+PH20, Lispro, Glulis+PH20, Glulis, Aspart+PH20, Aspart (Type: EXPERIMENTAL): All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout.~Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart.~Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart.~Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).